secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001171843-25-006885
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose TUSCANY abstract accepted for ASH 2025 poster session
------------------------------------------------------------

- Abstract #1645 from TUSCANY trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML selected for ASH 2025 poster presentation.
- Poster session December 6, 2025, 5:30-7:30 PM in Orlando, FL.
- Abstract available now; additional data to be presented in the poster.
- Aptose developing tuspetinib-based triple therapy for patients ineligible for induction chemo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325006885/0001171843-25-006885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325006885/f8k_103125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer